What is 503A compounding? A plain-English guide to how peptides reach patients

TL;DR

• 503A is bespoke and patient-specific; 503B is batch and facility-scale - two legal compounding tracks, different oversight, different bulks lists.
• 503A eligibility is a cascade, not a menu. A bulk substance qualifies if it meets a USP/NF monograph; if there is none, if it is a component of an FDA-approved drug; and only if neither applies, if it is on the 503A Bulks List. For most research peptides the list is the only remaining gate.
• Recommended ≠ listed ≠ approved - an advisory vote is a nonbinding opinion, listing needs HHS Secretary sign-off and a final rule, and no amount of listing ever becomes approval.
• On 23–24 July 2026 the PCAC voted in favour of six peptides - BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax - and against emideltide (DSIP).
• As of 19 October 2026 that is still Stage 1 of five: no proposed rule, no Secretary sign-off, not on the final 503A list, and no interim enforcement policy issued. A draft interim policy went to White House (OMB) review on 14 October 2026; it is not public, and enforcement discretion would add nothing to the list. Nothing is on the 503A list, and pharmacies are not yet authorised to compound these.
• No lawful route to compounding the six exists via this path today - every remaining step is outstanding, no completion date has been set, and no enforcement policy covering them has been issued.
• The machinery runs both ways - the FDA has proposed permanently excluding semaglutide, tirzepatide and liraglutide from the 503B list, which is Stage 3.
• October 2026's tirzepatide recall came from a 503B outsourcing facility, not a 503A pharmacy. A Class II recall means a possible temporary or reversible problem with specific batches; no illnesses were reported. It shows what the framework checks after the fact, not whether compounding as a whole is safe or unsafe, which has not been properly studied.

Educational content, not medical advice. This is a regulatory explainer, not a treatment recommendation. Any use of compounded medication is a physician-directed decision.

Updated 26 October 2026: adds the October 2026 compounded tirzepatide and NAD+ recall as a worked example of the 503A/503B split (the recalling firm is a registered 503B outsourcing facility, not a 503A pharmacy), what Class II means, and the dates of the FDA's 503B GLP-1 exclusion proposal (comment period closed 30 July 2026, no final decision announced).

Updated October 2026: adds the 14 October 2026 submission of the FDA's draft "Interim Access Policy for Compounding Using Certain Peptides" to OMB/OIRA review, the likely Category-1 enforcement-discretion mechanism, and what it would not do: approve nothing, add nothing to the 503A Bulks List, and not cover research-use-only products, dietary supplements, 503B or state boards. Status re-verified as at 19 October 2026; the five-stage position is unchanged.

Updated 28 September 2026: status only, no forecasts. Removed the "realistically runs into 2027" timeline estimate and the commentary about anticipated informal enforcement discretion, which together read as an implied waiting period; the accurate position is that no lawful route exists via this path today. Added the statutory 503A cascade (monograph, then approved-drug component, then the Bulks List). Replaced the pharmacy-verification checklist with the questions that belong to a prescriber.

Updated September 2026: re-verified the status as at 24 September 2026: the position is unchanged and is restated more plainly. Nothing is on the 503A Bulks List, and pharmacies are not yet authorised to compound the six recommended peptides. A PCAC vote is a recommendation and is not binding on the FDA; formal notice-and-comment rulemaking and HHS Secretary approval both remain outstanding.

Updated September 2026: pins the July 2026 vote to Stage 1 and confirms that as of 3 September 2026 the process has not advanced: no proposed rule published, the six recommended peptides not on the final Bulks List, no interim enforcement policy announced. Adds the next PCAC session, expected before the end of February 2027. Adds a plain definition of recommended ≠ listed ≠ approved, and names HHS Secretary sign-off as a required step in the sequence.

Updated August 2026: added a self-contained explainer on the five-stage federal rulemaking sequence (advisory vote → docket review → proposed rule → comment period → final rule), so the July 2026 PCAC vote can be read as one early step in a process rather than as a decision.

---

Compounding is one of those words that sounds technical and turns out to be simple: it's the practice of a licensed pharmacy preparing a medication tailored to a patient, rather than dispensing a mass-manufactured, FDA-approved product off the shelf. It's legal, long-standing, and - for peptides specifically - the pathway that almost every access debate is really about. Understanding it makes the headlines legible, and it also gives you the right questions to ask before accepting any compounded product.

The two compounding tracks: 503A vs 503B

US compounding runs on two legal pathways, named for sections of the Federal Food, Drug, and Cosmetic Act.

503A - patient-specific compounding. A traditional pharmacy prepares a medication for an individual patient pursuant to a prescription. The output is small-scale and bespoke. This is the track most relevant to prescribed peptide use.

503B - outsourcing facilities. A registered facility compounds in larger batches, often without a patient-specific prescription, to supply clinics and hospitals. 503B facilities are held to stricter, manufacturing-grade standards (current Good Manufacturing Practice) precisely because they operate at scale.

The simplest way to hold the distinction: 503A is bespoke and patient-specific; 503B is batch and facility-scale. Different rules, different oversight, different lists.

What the "bulk drug substances" lists are - and why they gate access

Compounding requires raw active ingredients - the "bulk drug substances." Both tracks have a list governing which substances may be used when there's no FDA-approved source:

• The 503A Bulks List governs patient-specific compounding.
• The 503B Bulks List governs outsourcing facilities.

For 503A, the statute sets these out as a cascade, not a menu. A pharmacy may compound with a bulk drug substance that:

1. meets an applicable USP or NF monograph, where one exists; or, if there is no monograph,
2. is a component of an FDA-approved drug; or, if neither applies,
3. appears on the 503A Bulks List.

Each step applies only when the one before it does not. Most research peptides have no monograph and are not components of any approved drug, so for them the Bulks List is the only remaining gate - which is exactly why every peptide-access fight is a fight about getting onto, or staying off, one of these lists. Describing list placement as the lawful route in general is wrong; describing it as the only remaining route for these particular substances is right.

How a peptide gets onto - or excluded from - a list

Additions and exclusions run through the FDA, informed by an advisory committee and a formal rulemaking process. That process has a fixed shape, and most of the confusion in peptide coverage comes from reporting an early step in it as though it were the last one. The sequence is set out in full immediately below, and two live 2026 examples then make the mechanics concrete.

Three words that are not synonyms: recommended, listed, approved

Before the stages, the definitions - because almost every misreading of 2026's peptide coverage comes from treating these three as interchangeable. They are not.

• Recommended - an advisory committee has voted in favour of a substance. That is a nonbinding opinion offered to the FDA. It changes no law, permits no compounding, and the agency is free to disagree with it. A recommendation does not put a substance on the 503A Bulks List, and does not make it compoundable today.
• Listed - the substance actually appears on the 503A (or 503B) Bulks List, following HHS Secretary sign-off and a completed final rule. Only now may a licensed pharmacy lawfully compound with it, under a patient-specific prescription. Listed still means permitted to compound, not proven to work.
• Approved - the FDA has reviewed a finished drug product for safety, efficacy and manufacturing quality and authorised it for marketing for a specific indication. No bulks-list placement is an approval, and no amount of listing ever becomes one. These are different regulatory objects, not different intensities of the same one.

Read in order: recommended ≠ listed ≠ approved. As of 19 October 2026, the six peptides recommended in July sit at the first of those three and nowhere near the second. Nothing is on the 503A list, and no pharmacy is yet authorised to compound with them.

From vote to rule: the five stages

This is the sequence every addition to - or removal from - a bulks list has to travel. It applies equally in both directions, and it is the same machinery whether the outcome is more access or less. Sibling articles on this site link down to this section rather than restating it.

Stage 1 - Advisory committee vote. The FDA convenes the Pharmacy Compounding Advisory Committee (PCAC), an external panel of clinicians, pharmacists and scientists, to review a substance against the agency's evaluation criteria and vote on whether it should be included. What it changes legally: nothing. A committee vote is advisory and nonbinding. It is a recommendation to the agency, not an agency decision, and the FDA is free to disagree with it.

Stage 2 - FDA docket review, and HHS Secretary sign-off. The agency takes the committee's recommendation, the public docket and its own scientific review and decides what, if anything, to propose. Sign-off by the HHS Secretary is a required step at this point, not a formality - a committee recommendation cannot become a proposed rule without it. What it changes legally: nothing. This stage is largely invisible from outside - there is no publication, no deadline the public can hold the agency to, and no guarantee it produces a proposal at all. The FDA retains sole authority over the Bulks List throughout.

Stage 3 - Proposed rule. If the agency decides to act, it publishes a proposed rule in the Federal Register setting out the intended change and its reasoning. What it changes legally: still nothing. A proposal is a statement of intent. Nothing may be compounded, marketed or supplied on the strength of it, and proposed rules are revised, narrowed and abandoned regularly.

Stage 4 - Public comment period. The proposal opens for written comment from clinicians, pharmacies, manufacturers, patient groups and the public - commonly a window of a couple of months, sometimes extended. The agency must consider the comments it receives. What it changes legally: nothing, but this is the stage at which the substance of the eventual rule is most likely to shift.

Stage 5 - Final rule. The agency publishes a final rule, with an effective date, responding to the comments and setting out the change. This is the only stage with legal force. Until a final rule takes effect, the list is whatever it was before, and pharmacies are bound by that.

How long does this take? There is no statutory clock, and honest coverage will not give you a date. The agency has left prior bulk-substance categories unresolved for long stretches, and a meaningful share of proposals never reach a final rule at all. Treat any specific "available by [month]" claim as marketing rather than reporting.

What a favourable vote still does not do, even if a final rule eventually follows:

• It does not make a substance an FDA-approved drug. Bulks-list inclusion permits compounding; it is not approval, and it involves no pre-market review of efficacy for any indication.
• It does not authorise direct-to-consumer sale. The 503A route runs through a licensed pharmacy, a prescriber and a patient-specific prescription.
• It does not legitimise "research use only" vendors, who are outside this framework entirely.
• It has no force outside the United States. Other countries register medicines through their own authorities; see access to medicines in Southeast Asia.

Where the July 2026 PCAC vote fits

The clearest worked example. On July 23–24, 2026, the PCAC reviewed seven peptides for the 503A list and voted in favour of six - BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax - and against one, emideltide (delta sleep-inducing peptide, DSIP). Six in, one out.

That was Stage 1, and as of 19 October 2026 it is still Stage 1. The votes were recommendations, and are not binding on the FDA; they did not make any of these substances lawful to compound. Nearly three months on, the FDA has not published a proposed rule, HHS Secretary approval has not been given, the six are not on the final 503A Bulks List, and no interim enforcement policy has been issued. Stated at its plainest: nothing is on the 503A list, and pharmacies are not yet authorised to compound these six peptides. Recommended, not listed, and nowhere near approved. The agency is not obliged to proceed at all, and no completion date has been set.

One claim circulates often enough to address directly: that the FDA will look the other way while rulemaking runs. No enforcement policy covering these six has been issued. No lawful route to compounding them exists via this path today. A pharmacy compounding with an unlisted bulk substance that has no monograph and is not an approved-drug component is doing something the statute does not authorise.

The interim policy at OMB: what it is and is not

On 14 October 2026 HHS/FDA submitted a draft "Interim Access Policy for Compounding Using Certain Peptides" to the Office of Information and Regulatory Affairs (OIRA), part of the White House Office of Management and Budget, for review. OIRA lists it as a notice pending review, with no legal deadline. It has not been issued and its text is not public, so which peptides, routes and conditions it would cover is not known.

• The likely mechanism. Law-firm analysis (not an FDA statement) expects interim enforcement discretion, possibly by placing certain peptides in Category 1 of the FDA's interim 503A bulks policy. In practice that would mean the FDA signalling it does not plan to act against 503A pharmacies compounding those peptides for individual patients, subject to conditions.
• It is not one of the five stages. Enforcement discretion sits outside the rulemaking sequence above. It approves no product, changes no statute and adds nothing to the 503A Bulks List; covered peptides would remain unapproved drugs, and the policy could be narrowed or withdrawn without notice-and-comment.
• What it would not cover. Per Holland & Knight, it would not reach research-use-only products, dietary supplements or the 503B outsourcing-facility channel, and it would not bind state boards of pharmacy or medicine, which keep their own authority over the pharmacies and prescribers they license.
• Timeline risk. FDA funding runs under a temporary spending measure through 11 December 2026. Until a final text is published, the accurate position is the one above: nothing has changed for these six.

A second PCAC session is expected before the end of February 2027, covering five further nominations: GHK-Cu, Melanotan II, cathelicidin (LL-37), dihexa acetate and PEG-MGF. That session will also be Stage 1 for those substances - a vote there would start the same five-stage clock, not shorten the one already running. The full recap is in the FDA vote results, the background in the 2026 reclassification explainer, and the single negative vote in DSIP and the rejected sleep peptides.

Where the GLP-1 503B exclusion fits

Movement runs the other way too. In 2026 the FDA proposed to permanently exclude semaglutide, tirzepatide and liraglutide from the 503B Bulks List, citing adverse-event reports tied to compounded versions (as of 31 May 2026, over 1,700 across compounded semaglutide and tirzepatide combined; earlier figures of 455+ and 320+ carried here were stale and have been corrected). That is Stage 3 - a proposed rule, not a final one. If finalised, it would close the main legal pathway for most mass-compounded GLP-1s. The detail is in is compounded GLP-1 legal?. Same machinery, opposite direction - which is the point: the lists both open and close access.

The dates, so the stage is clear: the FDA announced the proposal on 30 April 2026 with a Federal Register notice on 1 May 2026, then extended the comment period to 30 July 2026. As of 26 October 2026 we found no final decision announced. It is still a proposal. It does not directly change what 503A pharmacies may do.

A worked example: the October 2026 recall

In autumn 2026 a compounding recall made the news, and it is a useful test of whether the 503A and 503B labels make sense.

• Who. Apothecary Pharma, a North Carolina firm registered with the FDA as a 503B outsourcing facility. So this is a 503B story, not a 503A one. Headlines that said "compounding pharmacy" did not make that distinction.
• What. A voluntary recall of 22 lots (batches) of compounded tirzepatide injection and one lot of NAD+ injection, because the firm could not assure the products were sterile. It began on 24 September 2026.
• How serious. On 8 October 2026 the FDA classified it as Class II: using the product may cause temporary or medically reversible health problems, and serious harm is unlikely. The FDA notice reported no illnesses or injuries.
• Background. The FDA had sent the same firm a warning letter dated 1 December 2025 about insanitary conditions in its sterile production. The FDA has not said that letter caused this recall.
• Not the only one. FDA's enforcement report separately lists a Class II recall of compounded semaglutide syringes from Carolina Infusion, LLC, also over sterility assurance.

What the example teaches: 503B facilities sit under federal oversight and manufacturing-grade standards precisely because they make batches at scale, and a recall is one of the ways that oversight shows up. A recall is a decision about specific batches and how they were made. It is not a verdict on a molecule, and it is not a finding about 503A pharmacies. If a medicine you use appears on a recall list, that is a conversation with your own prescriber, today.

What compounding does - and does not - guarantee about quality

This is the part that actually protects you, and it's routinely misunderstood.

Compounded is not the same as FDA-approved. An FDA-approved drug has been through pre-market review of safety, efficacy and manufacturing; a compounded preparation has not - it's permitted under the compounding framework, not approved as a finished drug. ("FDA-approved" is itself less uniform than it sounds - there are several distinct pathways and designations, and what accelerated approval actually means untangles which one proves what.) That doesn't make compounding illegitimate (it's a real, regulated practice), but it does mean the quality of what you receive depends heavily on who compounded it and from what source material. A reputable 503A pharmacy using verified active ingredients is a very different thing from a grey-market "research use only" vendor invoking the word "compounded" as marketing.

So the honest bottom line: the legal category is the first question, not the last. Two things follow from it that a reader can hold without assessing anyone:

• A compounded medicine in the lawful sense starts with a prescriber who has assessed you and a patient-specific prescription. A direct-to-consumer sale is not 503A compounding, whatever it calls itself.
• A substance that is not permitted under the cascade above is not made lawful by the word "compounded" or by a "research use only" label.

Whether a particular preparation is appropriate for you is a question for the prescriber, who carries the responsibility for it. How to choose a peptide clinic covers what a legitimate clinical encounter looks like.

Frequently asked questions

Is compounded the same as FDA-approved? No. FDA-approved drugs undergo pre-market review of safety, efficacy and manufacturing. Compounded preparations are permitted under the 503A/503B framework but are not approved finished drugs - quality depends on the pharmacy and its source material.

Does an advisory committee vote change the law? No. A PCAC vote is advisory and nonbinding - Stage 1 of five. The list only changes when the FDA publishes a final rule that takes effect, after docket review, HHS Secretary sign-off, a proposed rule and a public comment period.

What's the difference between recommended, listed and approved? Recommended means an advisory panel voted in favour - a nonbinding opinion that does not place a substance on the 503A Bulks List and does not make it compoundable today. Listed means the substance is actually on the list, after HHS Secretary sign-off and a final rule, and may lawfully be compounded under a prescription. Approved means the FDA has cleared a finished drug product for marketing for a specific indication. Recommended ≠ listed ≠ approved, and no amount of listing ever becomes approval.

When will the six peptides recommended in July 2026 become compoundable? There is no date, and anyone offering one is guessing. As of 19 October 2026 the FDA has not proposed a rule on them, is not required to, and HHS Secretary approval has not been given. Nothing is on the 503A list, and no pharmacy is yet authorised to compound with these substances. A committee recommendation is not an approval.

Isn't the FDA letting pharmacies compound them in the meantime? No policy to that effect has been issued. A draft interim policy has been under White House (OMB) review since 14 October 2026, but its text is not public. If it takes the expected enforcement-discretion form, it would describe where the FDA chooses not to act against 503A pharmacies; it would not add anything to the 503A list, would not cover research-use-only products, supplements or 503B, and would not bind state boards. Until a final rule takes effect, the list is what it was.

Is 503A compounding safe? It can be, when done by a licensed pharmacy using verified ingredients under a legitimate prescription. The risk rises sharply with unverified sourcing and direct-to-consumer "research" sales that borrow the language of compounding without the oversight.

Why were GLP-1s restricted from compounding? The FDA proposed in April 2026 to permanently exclude semaglutide, tirzepatide and liraglutide from the 503B list, citing adverse-event reports linked to compounded versions. The comment period closed on 30 July 2026, and as of 26 October 2026 no final decision had been announced, so it is still a proposal (Stage 3). If finalised, it closes the main legal route for most mass-compounded GLP-1s.

Was the October 2026 tirzepatide recall a 503A problem? No. The recalling firm is registered with the FDA as a 503B outsourcing facility. The recall was Class II, covered specific batches, and no illnesses were reported.

Related reading

• After the FDA vote: what changed · Are peptides legal now? The 2026 timeline · The 2026 FDA peptide reclassification · Which peptides are legal in 2026 · BPC-157, KPV and the 2026 compounding question · DSIP and the rejected sleep peptides · Is compounded GLP-1 legal? · How to choose a peptide clinic · What accelerated approval actually means
• Part of The Complete Guide to Peptides

---

Where Vivre Labs fits. Vivre Labs offers semaglutide, a prescription medicine approved for weight management and type 2 diabetes, and tirzepatide, approved for the same uses. Whatever you are considering, we recommend starting with baseline bloodwork, so there is a measured starting point to compare against.

---

Educational content, not medical advice. This explainer describes the US compounding framework in general terms; regulatory status changes and varies by jurisdiction. Compounded preparations are not FDA-approved finished drugs. Any use of compounded medication is a physician-directed decision. Claims for the Malaysian market are subject to MAB requirements. Regulatory picture as of 26 October 2026. Last reviewed: October 2026.

References

• Federal Food, Drug, and Cosmetic Act, Sections 503A (patient-specific compounding) and 503B (outsourcing facilities); 503A and 503B Bulk Drug Substances Lists and the evaluation criteria FDA/PCAC apply; notice-and-comment rulemaking under the Administrative Procedure Act (proposed rule → public comment → final rule). · FDA Advisory Committee Calendar, Pharmacy Compounding Advisory Committee meeting, 23–24 July 2026: votes in favour of BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax for the 503A list and against emideltide (DSIP) - https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026 · Buchanan Ingersoll & Rooney, "FDA Voted Yes on Six Peptides - Now What? The Regulatory Road Ahead" (advisory votes nonbinding; FDA retains sole authority over the Bulks List; rulemaking sequence; HHS Secretary approval required before a recommendation can be carried into rulemaking - not given as of 24 September 2026; PCAC votes are recommendations and are not binding on FDA; nothing added to the 503A Bulks List and pharmacies not authorised to compound the six) - https://www.bipc.com/fda-voted-yes-on-six-peptides-now-what-the-regulatory-road-ahead · Health Affairs Forefront, "FDA Advisory Committee's Vote May Open Drug Compounding Back Door To Unapproved Peptides" - https://www.healthaffairs.org/content/forefront/fda-advisory-committee-s-vote-may-open-drug-compounding-back-door-unapproved-peptides · FDA proposed rule (2026) to permanently exclude semaglutide, tirzepatide and liraglutide from the 503B Bulks List, citing adverse-event reports for compounded versions (as of 31 May 2026, over 1,700 combined across compounded semaglutide and tirzepatide; the 455+/320+ figures previously carried here were stale and are superseded - see is compounded GLP-1 legal?). · Draft "Interim Access Policy for Compounding Using Certain Peptides" submitted to OIRA/OMB for review on 14 October 2026 (not issued; text not public; expected enforcement-discretion / Category 1 mechanism; would not cover research-use-only products, dietary supplements or 503B; would not bind state boards) - Holland & Knight, "Peptides at a Crossroads" (October 2026) (https://www.hklaw.com/en/insights/publications/2026/10/peptides-at-a-crossroads-what-wellness-providers-need-to-know); Buchanan Ingersoll & Rooney, 16 October 2026 (https://www.bipc.com/fda-submits-interim-peptide-compounding-policy-for-white-house-review-what-pharmacies-should-know); Becker's Hospital Review, 15 October 2026 (https://www.beckershospitalreview.com/glp-1s/hhs-sends-peptide-compounding-plan-to-white-house-5-things-to-know/). · Compounded preparations are not FDA-approved. · FD&C Act section 503A(b)(1)(A)(i): bulk drug substances must comply with an applicable USP/NF monograph if one exists; if not, be a component of an FDA-approved drug; if neither, appear on the 503A Bulks List - FDA, "Bulk Drug Substances Used in Compounding Under Section 503A" (https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act).
• October 2026 recall: Becker's Hospital Review, "Compounded GLP-1 injections recalled nationwide: 4 notes", 20 October 2026 (https://www.beckershospitalreview.com/glp-1s/compounded-glp-1-injections-recalled-nationwide-4-notes/); BioPharma Dive, 22 October 2026 (https://www.biopharmadive.com/news/glp1-obesity-drug-recall-apothecary-tirzepatide-zepbound/833712/); FDA warning letter 717972 to Apothecary Pharma LLC, 1 December 2025, identifying it as a registered 503B outsourcing facility (fda.gov); Peptide Briefs, 25 October 2026, on the FDA enforcement report entry for Carolina Infusion, LLC (https://peptidebriefs.substack.com/p/a-sterility-recall-a-regulatory-signal).
• FDA proposal not to include semaglutide, tirzepatide and liraglutide on the 503B Bulks List: announced 30 April 2026, 91 Fed. Reg. 23431 (1 May 2026); comment period extended to 30 July 2026, Federal Register 26 June 2026 (https://www.govinfo.gov/content/pkg/FR-2026-06-26/html/2026-12937.htm).